Skip to main content
Oferta
Oferta
Integrated Biologics
Integrated Biologics
Tecnologías de expresión
Tecnologías de expresión
GS Xceed® Gene Expression System
GS piggyBac® Transposon Technology
GS Effex® Cell Line
GS Discovery® Transient Expression
bYlok® Bispecific Pairing Technology
XS Technologies®
Soporte técnico
Early Derisking and Optimization
Early Derisking and Optimization
Developability Assessment
Manufacturability Assessment
Antibody Humanization and Deimmunization
Protein Engineering
Potency Assessment
Immunogenicity / Immunotoxicity Assessment
Rapid Host Screen and Early Protein Expression
Producción no conforme a las BPF
Epibase® in vitro and in silico Screening
Mammalian Biopharmaceutical Services
Mammalian Biopharmaceutical Services
Ibex® Design mAbs DNA-to-IND Program
Ibex® Design Bispecifics DNA-to-IND Program
Ibex® Design Fabs and Fc-Fusion Proteins DNA-to-IND Programs
Ibex® Design Scaffolds and other Recombinant Proteins
Cell Line Development
Tailored License Application Program
Desarrollo del proceso
Desarrollo analítico
Drug Substance Manufacturing
Parenteral Drug Product Services
Parenteral Drug Product Services
Clinical Technology Transfers
Biologics Formulatability
Product Formulation Development
Desarrollo analítico
Desarrollo del proceso
Biologics Special Services
Drug Product Manufacture
Biologics Regulatory Services
Centro de conocimientos
Advanced Synthesis
Advanced Synthesis
Moléculas pequeñas
Moléculas pequeñas
Drug Substance/API Services
Drug Substance/API Services
API Support for Early Phase Development
AI-Enabled Route Scouting Service
Solid Form Drug Services
PBPK Modeling Services
Pharmaceutical Method Development
Commercial API Manufacturing Services
Highly Potent API Technologies
Highly Potent API Technologies
HPAPI Handling and Development
HPAPI Manufacturing | Low & High Potency
ADC Clinical and Commercial Manufacturing
ADC Payload Product Development
Ingeniería de partículas
Ingeniería de partículas
Solid Dispersion Technology
Mejora de la biodisponibilidad
Spray-Dried Dispersion Technology
Micronization and Jet Milling
Hot Melt Extrusion
Producto farmacológico
Producto farmacológico
SimpliFiH® Solutions
Drug Product Technologies
Drug Product Technologies
Specialized Drug Product Development
Micro-dosing for Early Human Clinical Studies
Clinical Trial Material Manufacture, Supply
Clinical Bottling, Labelling and Supply
Formulation and Development
Design and Preformulation Development
Drug Development Workflow & Pharmaceutical Process Optimization
Pediatric Drug Product Development
Inhalation Formulation Development
Ofertas integradas
Regulatory Affairs CMC Services
Regulatory Affairs CMC Services
CMC Development Services | CMC Regulatory Submissions
Bioconjugates Services
Bioconjugates Services
Early Development Bioconjugates | ADC
ADC Drug Substance Manufacturing
Pharmaceutical, ADC Analytical Services
Targeting Agent and Carrier Protein
ADC Process Development
Ibex® Design ADC, DNA-to-IND Program
Centro de conocimientos
Specialized Modalities
Specialized Modalities
Células y genes
Células y genes
Desarrollo del proceso
Producción conforme a las BPFa
Alogénico
Autólogo
Vectores virales
Exosomas
Plataforma Cocoon®
Microbios
Microbios
Microbial Strain Development
Desarrollo del proceso
Drug Substance Manufacturing
Desarrollo analítico
mRNA/LNP
mRNA/LNP
Desarrollo del proceso
Analytical Services
mRNA Manufacturing
Lipid Nanoparticles Encapsulation
Productos biocientíficos
Centro de conocimientos
Centro de conocimientos
Compañía
Compañía
Acerca de nosotros
Acerca de nosotros
Our One Lonza Strategy
Our Leadership
Our Leadership
Executive Committee
Board of Directors
Board Committees
Our History
Our Locations
Noticias y medios
Noticias y medios
Comunicados de prensa
Imágenes y videos
Pautas sobre el logo
Blog
A View On - Lonza Podcast
Consultas de los periodistas
Relaciones con los inversores
Relaciones con los inversores
Shareholders and Stock Information
Shareholders and Stock Information
Consenso y analistas
Bond Investors and Credit Information
Investor FAQ
Share Buyback
Calendario y eventos
Informes y presentaciones
Gobernanza corporativa
Ética y cumplimiento
Consultas de los inversores
Sustentabilidad
Sustentabilidad
Medioambiente
Personas y sociedad
Cumplimiento e integridad
Adquisición responsable de materiales
Calidad Global
Empleo
Empleo
Welcome to Lonza
La vida en Lonza
Employee Benefits
Early Career Opportunities
Inclusion, Diversity and Belonging
Únase a nuestra comunidad de talentos
Contact
Search
Cancel
Shareholders and Stock Information
Inicio
Relaciones con los inversores
Shareholders and Stock Information
Major shareholders according to SIX Swiss Exchange Disclosure Office
(as of 18 March 2025)
BlackRock, Inc.: 9,85%
UBS Fund Management (Switzerland) AG: 6,246%
Lonza Group AG: 3,002%
Find historical shareholding disclosures on the
SIX Exchange Regulation website
.
Shareholder resources
Consenso y analistas
Overview of sell-side analysts that cover Lonza on a regular basis, and our consensus forecasts.
Más información
Bond Investors and Credit Information
Credit Ratings: View the assessments of Lonza. Information for credit analysts, debt investors and rating agencies.
Más información
Informes y presentaciones
All Lonza’s financial and non-financial reports, presentations and key company updates available in the Reporting Center.
Más información
Share Buyback
Overview of Lonza’s current share buyback program.
Más información
Investor FAQ
Overview of key investor relevant topics addressed by Lonza about its shares, general finance and investor relations services.
Más información
Anterior
Siguiente
Configuración de cookies
|
Términos y condiciones
|
Exención de responsabilidad legal
|
Política de privacidad